{"id":107906,"date":"2024-03-01T15:39:55","date_gmt":"2024-03-01T10:09:55","guid":{"rendered":"http:\/\/finservwealth.com\/strong-india-growth-benign-price-erosion-in-the-us-drive-q3-earnings-for-indian-pharma\/"},"modified":"2024-03-01T15:39:55","modified_gmt":"2024-03-01T10:09:55","slug":"strong-india-growth-benign-price-erosion-in-the-us-drive-q3-earnings-for-indian-pharma","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/strong-india-growth-benign-price-erosion-in-the-us-drive-q3-earnings-for-indian-pharma\/","title":{"rendered":"Strong India growth, benign price erosion in the US drive Q3 earnings for Indian pharma"},"content":{"rendered":"<p> Indian generic companies have benefited from the continuing shortages and approval slowdown in the US.<\/p><div id=\"finse-3068441249\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/business\/strong-india-growth-benign-price-erosionthe-us-drive-q3-earnings-for-indian-pharma_17483301.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Indian generic companies have benefited from the continuing shortages and approval slowdown in the US. Indian generic companies have benefited from the continuing shortages and approval slowdown in the US.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/business\/strong-india-growth-benign-price-erosionthe-us-drive-q3-earnings-for-indian-pharma_17483301.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> Indian generic companies have benefited from the continuing shortages and approval slowdown in the US.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/business\/strong-india-growth-benign-price-erosionthe-us-drive-q3-earnings-for-indian-pharma_17483301.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Indian generic companies have benefited from the continuing shortages and approval slowdown in the US. Indian generic companies have benefited from the continuing shortages and approval slowdown in the US.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/business\/strong-india-growth-benign-price-erosionthe-us-drive-q3-earnings-for-indian-pharma_17483301.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> Indian generic companies have benefited from the continuing shortages and approval slowdown in the US.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-107906","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2023\/200x200\/M\/MixCollage-24-Dec-2023-05-04-PM-9076_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/107906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=107906"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/107906\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=107906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=107906"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=107906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}